Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
Public ClinicalTrials.gov record NCT02898207. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors With Expansion in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase I trial studies the side effects and best dose of olaparib and onalespib when given together in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable) or ovarian, fallopian tube, primary peritoneal, or triple-negative breast cancer that has come back (recurrent). Olaparib and onalespib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study identification
- NCT ID
- NCT02898207
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 28 participants
Conditions and interventions
Conditions
- Metastatic High Grade Fallopian Tube Serous Adenocarcinoma
- Metastatic Malignant Solid Neoplasm
- Metastatic Primary Peritoneal Serous Adenocarcinoma
- Metastatic Triple-Negative Breast Carcinoma
- Platinum-Resistant Fallopian Tube Carcinoma
- Platinum-Resistant Ovarian Carcinoma
- Platinum-Resistant Primary Peritoneal Carcinoma
- Recurrent Breast Carcinoma
- Recurrent High Grade Fallopian Tube Serous Adenocarcinoma
- Recurrent High Grade Ovarian Serous Adenocarcinoma
- Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma
- Recurrent Triple-Negative Breast Carcinoma
- Refractory Fallopian Tube Serous Adenocarcinoma
- Refractory Ovarian Serous Adenocarcinoma
- Refractory Primary Peritoneal Serous Adenocarcinoma
- Refractory Triple-Negative Breast Carcinoma
- Unresectable High Grade Fallopian Tube Serous Adenocarcinoma
- Unresectable Malignant Solid Neoplasm
- Unresectable Primary Peritoneal Serous Adenocarcinoma
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 19, 2017 (Actual)
- Primary completion
- Jul 29, 2020 (Actual)
- Completion
- Jan 14, 2022 (Actual)
- Last update posted
- Apr 26, 2023
2017 – 2022
United States locations
- U.S. sites
- 8
- U.S. states
- 4
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Hospital in Arizona | Phoenix | Arizona | 85054 | — |
| Mayo Clinic in Arizona | Scottsdale | Arizona | 85259 | — |
| Mayo Clinic in Florida | Jacksonville | Florida | 32224-9980 | — |
| Massachusetts General Hospital Cancer Center | Boston | Massachusetts | 02114 | — |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02898207, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 26, 2023 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02898207 live on ClinicalTrials.gov.